article thumbnail

Progress Toward a New GAD Treatment Paradigm

Fierce BioTech

Robert Barrow, Chief Executive Officer of MindMed | Generalized anxiety disorder afflicts millions however, the latest treatment was approved in 2007. Now MindMed is advancing a new treatment paradigm.

article thumbnail

Automated red blood cell exchange: bridging treatment gaps in sickle cell disease care

Drug Target Review

Dr Aaron Haubner, Senior Manager of North America Medical Affairs and Market Access at Terumo Blood and Cell Technologies , reveals that while promising new treatments emerge, urgent partnerships are needed to ensure this essential blood therapy reaches the patients who need it most.

Disease 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gepirone

New Drug Approvals

4] It was approved for the treatment of major depressive disorder in the United States in September 2023. [4] 4] It was approved for the treatment of major depressive disorder in the United States in September 2023. [4] 4] It was approved for the treatment of major depressive disorder in the United States in September 2023. [4]

FDA 62
article thumbnail

Therapeutic peptide developed for triple-negative breast cancer

Drug Target Review

These findings offer a novel strategy for developing targeted treatments for triple-negative breast cancer, which currently has no approved options. The team also observed that the drug prevented in vitro cancer stem cells from self-renewing, which is a characteristic of aggressive cancer cells that supports treatment resistance.

Treatment 105
article thumbnail

BioSensics Joins KIF1A.ORG’s Mission to Support KAND Natural History Study

KIF1A

By building a richer dataset, we not only improve our understanding of the progression and variability of KAND, but also make significant strides toward being clinical trial ready when a treatment becomes available. We are honored to partner with such passionate and visionary leaders in the rare disease community.

article thumbnail

Investigating antipsychotics in a Parkinson’s disease psychosis model

Drug Target Review

Treatment with mesdopetam counteracted both these features of the psychosis model, ie, restored normal levels of synchronisation and reduced HFOs. In rodents, non-human primates, as well as humans, long-term treatment with levodopa has been associated with an increase in dopamine D3 receptor expression.

Disease 105
article thumbnail

The role of STRIs in cancer

Drug Target Review

In cancer, the eIF4F complex becomes dysregulated, leading to the excessive production of these proteins, which contribute to tumour formation and resistance to treatment. STRIs represent a fundamentally different approach to cancer therapy compared to traditional treatments like chemotherapy, radiation therapy, and targeted therapies.